Hanmi Science Co Osake

Hanmi Science Co EBITDA per osake

EBITDA per osake yhtiöstä Hanmi Science Co (008930.KS) 10.8.2026 päivämäärällä on 703,96 KRW. Edellisenä vuonna EBITDA per osake oli 967,46 KRW — muutos −27,24 % (matalampi).

EBITDA per osake

703,96KRW

YoY

−27,24%

Viimeksi päivitetty:

EBITDA per osake yhtiöstä Hanmi Science Co on 2026 703,96 KRW. EBITDA per osake yhtiöstä Hanmi Science Co oli 2025 967,46 KRW. Se laskee −27,24% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Hanmi Science Co Osakeanalyysi

Mitä Hanmi Science Co tekee? Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Hanmi Science Co osakkeesta

Yhtiön Hanmi Science Co EBITDA per osake on 703,96 KRW vuonna 2026.

EBITDA per osake yhtiöstä Hanmi Science Co muuttui arvosta 967,46 KRW arvoon 703,96 KRW, mikä edustaa −27,24 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA per osake Hanmi Science Co:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA per osake jakaa EBITDAN liikkeeseen laskettujen osakkeiden lukumäärällä, näyttäen operatiivisen rahavoiton jaettuna osakemäärällä ennen poistoja ja rahoitusvaikutuksia.

Access this data via the Eulerpool API

Tuloslaskelma — Hanmi Science Co

Kaikki tunnusluvut — Hanmi Science Co